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The effectiveness of two activation techniques, collision activated dissociation (CAD) and
infrared multiphoton dissociation (IRMPD), is compared for structural characterization of
protonated and lithium-cationized macrolides and a series of synthetic precursors in a
quadrupole ion trap (QIT). Generally, cleavage of the glycosidic linkages attaching the sugars
to the macrolide ring and water losses constitute the major fragmentation pathways for most
of the protonated compounds. In the IRMPD spectra, a diagnostic fragment ion assigned as the
desosamine ion is a dominant ion that is not observed in the CAD spectra because of the higher
m/z limit of the storage range required during collisional activation. Activation of the
lithium-cationized species results in new diagnostic fragmentation pathways that are partic-
ularly useful for confirming the identities of the protecting groups in the synthetic precursors.
Multi-step IRMPD allows mapping of the fragmentation genealogies in greater detail and
supports the proposed structures of the fragment ions. (J Am Soc Mass Spectrom 2002, 13,
630–649) © 2002 American Society for Mass Spectrometry
Interest in the analysis of macrolide antibiotics hasgrown in recent years as new compounds, resultingfrom the manipulation of the biosynthetic pathways
of Streptomyces bacteria, may offer improved activities
against antibiotic-resistant bacteria [1]. Novel analogs of
macrolide compounds are also produced from modifi-
cations of erythromycin during attempts at total syn-
thesis [2]. The clinical testing of these erythromycin
analogs for bacteriostatic potential, possible human
toxicity, and pharmacokinetics requires effective analyt-
ical techniques. Mass spectrometry has been utilized in
several recent studies aimed at identifying the struc-
tures and fragmentation pathways of macrolide antibi-
otics [3–9]. For example, Gross and co-workers used fast
atom bombardment (FAB) to create both protonated
and alkali metal cationized species of erythromycin A,
megalomicin A, desmycosin, megalalosamine, and tylo-
sin, followed by CAD for structural characterization [3].
They noted that the protonated macrolides gave frag-
mentation patterns that lacked mid-range fragment
ions, whereas the alkali metal cationized species gave a
greater variety of fragment ions. Gates et al. used
isotopic labeling to determine the origin of the initial
water loss from protonated erythromycin [4, 5]. For
these studies, electrospray ionization (ESI) was used to
introduce samples into either a Fourier transform ion
cyclotron resonance (FTICR) mass spectrometer (for
accurate mass measurements), a quadrupole-time-of-
flight (Q-TOF) instrument, or a quadrupole ion trap for
MS/MS experiments. Based on the 18O-labeling, it was
found that the first loss of water occured from the C-9
carbonyl group, indicating that the carbonyl oxygen
was protonated, not the more basic amine group in the
desosamine moiety. They also confirmed via MSn ex-
periments that the first macrolide ring cleavage in-
volved the C-13 position and adjacent oxygen, with the
net loss identified as a substituted ketone moiety [4].
Volmer and Hui incubated erythromycin in aqueous
solutions at non-physiological pH [6], and subsequently
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used solid phase microextraction/high performance
liquid chromatography/ESI-MS to determine the de-
composition products of protonated erythromycin in a
triple quadrupole mass spectrometer. Ling et al. dem-
onstrated the use of matrix assisted laser desorption
ionization (MALDI) TOF-MS to quantify numerous
classes of antibiotics, including macrolides, from meth-
anol solutions using an internal standard [9].
The structural characterization of macrolides by
mass spectrometry has proven to be an ongoing analyt-
ical challenge because of the low number of diagnostic
fragment ions in the CAD spectra of the protonated
molecules. For example, protonated macrolides typi-
cally lose water molecules in succession as the domi-
nant dissociation pathways [5]. Another recognized
feature of the dissociation behavior of protonated mac-
rolides is their tendency to lose their sugar functional
groups while the large, flexible macrolide ring remains
largely intact. Confirmation of the type of sugars or
other substituents at carbons 3, 5, and 11 (Figure 1) is a
key issue in the characterization of new analogs. The
use of other activation and ionization methods may
provide an avenue for addressing the challenging struc-
tural characterization problems associated with the
analysis of macrolides.
In the present study, CAD and IRMPD are used to
characterize three macrolide compounds and four pre-
cursors of an in vitro total synthesis of erythromycin B
(Figure 1). Lithium cationization was also evaluated as
a potential means of providing complementary struc-
tural information obtained from fragmentation. Alkali
metal cationization in general has been explored in
Figure 1. Structures of macrolides (molecular weight in Da).
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recent years as an alternative to conventional protona-
tion in electrospray ionization and as a means to change
the sites of charge localization and promote different
fragmentation processes [10–15]. In this report, the
fragmentation promoted by CAD and IRMPD methods
(including multi-stage tandem mass spectrometry
[MSn]) is compared, along with an evaluation of the
diagnostic utility of the fragmentation patterns ob-
tained from the protonated versus lithium-cationized
macrolides. A focal point was to determine the best
manner for confirming the substituents (i.e., protecting
groups and/or sugars for the synthetic precursors)
present in the macrolides that would allow confident
identification of the structures.
Infrared multiphoton dissociation has been shown to
be a viable alternative to CAD for probing molecular
structures in trapping instruments [16–29]. In some
cases, IRMPD proves to be more efficient than CAD,
making it more suitable for MSn experiments. This
advantage results from the fact that IRMPD does not
appreciably alter the kinetic energy or stable orbits of
the trapped ions. Collisional techniques, however, may
lead to ion scattering during energetic collisions in-
tended to excite them internally. Furthermore, in quad-
rupole ion traps, IRMPD is effective regardless of the
trapping potential applied to the ring electrode. Thus,
the low-mass cut-off can be maintained at a sufficiently
low level that fragments over a wide mass range can be
stored and detected. For example, the most effective
CAD conditions typically allow trapping of fragment
ions that have mass-to-charge values that are at least
33% of that of the precursor ion, whereas the IRMPD
conditions allow storage of fragment ions that might
have mass-to-charge values that are only 10% of the
mass-to-charge of the parent ion. The possibility of
performing MSn by using discreet states of irradiation
and isolation can be advantageous for probing geneal-
ogies of dissociation while maintaining highly efficient
trapping conditions. One potential downside of IRMPD
is that activation is less efficient at higher pressures
because of the competition from collisional cooling;
however, trapping is less effective at lower pressures. A
strategy for alleviating this trade-off has been reported
recently by the combination of IRMPD with heating of
the trap, thus improving energy deposition while main-
taining satisfactory trapping efficiency by allowing use
of higher pressures [29]. Although not used in the
present application because of the naturally high disso-
ciation efficiencies of the erythromycin compounds,
heating should offset this drawback of IRMPD for other
applications.
Experimental
Two QIT mass spectrometers with electrospray ioniza-
tion sources were used. The first instrument was an
in-house built QIT system that utilized modified Finni-
gan ITD electronics and software with an ESI source
Figure 2. (a) CAD and (b) IRMPD of protonated erythromycin A. Figure 3. (a) CAD and (b) IRMPD of protonated SP3.
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Table 1. CAD and IRMPD data for protonated molecules
Compound
Parent
(m/z)
Fragments
(m/z)
Neutral
loss
CAD Results
Percent
IRMPD Results
Percent
Erythromycin A 734 716 18 24% 6%
698 36 9% 6%
576 158 41% 21%
558 176 11% 6%
540 194 5% 6%
522 212 8% 10%
316 418 2% 2%
158 576 — 40%
116 620 — 3%
Erythromycin B 718 700 18 38% 12%
560 158 22% 11%
542 176 10% 8%
524 194 27% 57%
316 402 3% 1%
158 560 — 10%
116 604 — 1%
Oleandomycin 688 616 72 2% —
544 144 86% 42%
387 301 1% —
369 319 2% —
351 337 1% —
302 386 8% —
158 530 — 54%
116 572 — 4%
SP1 720 702 128 1% —
562 158 97% 42%
544 176 1% 2%
316 404 1% 1%
176 544 — 2%
158 562 — 49%
116 606 — 4%
SP2 562 544 18 62% 3%
405 157 8% —
387 175 5% 1%
369 193 2% —
351 211 3% 2%
267 295 6% 2%
176 386 2% 3%
158 404 12% 75%
138 424 — 2%
116 448 — 12%
SP3 692 674 18 4% 1%
610 82 1% —
544 148 62% 24%
535 157 20% 1%
526 166 5% 2%
517 175 1% 1%
387 305 5% 2%
369 323 1% 1%
351 341 1% 2%
267 425 1% 2%
176 516 — 6%
158 534 — 53%
138 554 — 3%
116 578 — 4%
SP4 653 635 18 1% 1%
517 136 64% 13%
(continued)
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and interface modeled after the Oak Ridge National
Laboratory design [30]. A stored waveform inverse
Fourier transform (SWIFT) system controlled by TTL
triggers in the scan function was used for resonant
ejection and was described in detail previously [17].
IRMPD experiments were performed with a model 575
Apollo (Apollo Lasers, Chatsworth, CA) continuous-
wave CO2 laser used in conjunction with a Uniblitz
shutter (Vincent Associates, Rochester, NY). The center
of the trap was irradiated through a ZnSe window
(II-VI Incorporated Saxonburg, PA) in the vacuum
chamber aligned with a 6 mm hole drilled radially in
the ring electrode [17]. The IRMPD laser irradiation was
varied between 1 and 1000 ms as needed at a flux of 45
W/cm2.
For the IRMPD experiments, solutions of each mac-
rolide were made up in methanol at concentrations of
5  104 M. For lithium complexation experiments,
equal volumes of 5  103 M metal salt solution and
aminoglycoside solution were combined to provide a 10
times metal excess. Electrospray of the solutions was
undertaken at a needle voltage of 4.0 kV and a flow rate
of 3 uL/min. The chamber pressure was typically 0.1
mtorr (uncorrected) based on the mixture of air and
solvent admitted through the ESI orifice; addition of an
auxiliary bath gas was unnecessary. Note that this
Scheme 1
Table 1. Continued
Compound
Parent
(m/z)
Fragments
(m/z)
Neutral
loss
CAD Results
Percent
IRMPD Results
Percent
505 148 3% 1%
487 166 2% 4%
369 284 13% 13%
351 302 13% 29%
333 320 2% 9%
— 387 — 5%
241 412 2% 7%
— 429 — 9%
— 533 — 9%
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pressure is so high that helium is never routinely added
to this system, even for CAD experiments. This is
clearly an artifact of the ESI interface design, and other
ESI/quadrupole ion trap systems typically require the
use of helium to improve trapping efficiencies.
CAD experiments were performed on a Finnigan
LCQ-Duo using the Xcalibur (Finnigan, San Jose, CA)
software package and the electrospray source. The
solutions utilized were the same as those previously
described, diluted by a factor of ten. The pressure was
maintained at nominally 5  106 torr with helium in
the absence of ESI. For ESI experiments, the sample
flow rate was 3 L/min, and the pressure in the
analyzer region was then nominally 1  105 torr with
helium buffer gas. Ionization and trapping conditions
were optimized for each of the macrolides; re-tuning for
individual samples was seldom necessary.
Erythromycin A and B and oleandomycin were
obtained from Sigma Chemical (St. Louis, MO). SP1 and
SP2 were degraded from natural erythromycin B [31].
SP3 [32] and SP4 [33] were prepared by synthetic
methods.
Results and Discussion
Protonated Macrolides and Analogs
For simplicity in discussing the four synthetic precur-
sors, each is assigned an abbreviated designation: Syn-
thetic precursor (SP1–4), as shown in Figure 1. Exam-
ples of the CAD and IRMPD spectra for two of the
protonated macrolides are shown in Figures 2 and 3 for
erythromycin A and SP3. The CAD data was obtained
by using the commercial LCQ instrument, whereas the
IRMPD data was obtained with the home-built ion trap
instrument because it was felt that the CAD data from
the LCQ instrument would be more useful to the
growing number of users of commercial ion trap instru-
ments. Thus, in this report the best CAD data (from the
LCQ ion trap) is compared to the best IRMPD data
available (from the home-built instrument). Both CAD
and IRMPD data for all seven protonated compounds
are summarized in Table 1. The most prevalent frag-
mentation pathways include dehydration (for four of
the macrolides) and loss of the cladinose sugar (for the
four that possess the cladinose moiety) (Scheme 1). In
the IRMPD spectra, the formation of a characteristic
desosamine ion at m/z 158 for protonated erythromycin
A and B, SP1, SP2, and SP3 is also significant (Scheme
1). This fragment ion is not observed in the analogous
CAD spectra because the mass is too low to be trapped
efficiently under the conditions needed for activation of
the high mass precursors. The schemes presented in this
work offer proposed fragment ion structures that are
consistent with genealogical pathways and secondary
fragmentation information obtained from multi-stage
IRMPD (MSn) experiments, as discussed later.
The IRMPD and CAD spectra of protonated eryth-
romycin A have comparable signal intensities, dissoci-
ation efficiencies, and fragment ions (Figure 2), with the
notable exception of the absence of the characteristic
desosamine ion at m/z 158 in the CAD spectrum. Both
spectra show two water losses, loss of the cladinose
sugar (158 a, formation of m/z 576), and further
water losses from the macrolide ring. Protonated eryth-
romycin B displays one less loss of water than erythro-
mycin A in both the IRMPD and CAD spectra (Figure
4), implying that the C-12 hydroxyl accounts for this
extra step of dehydration in protonated erythromycin
A. Protonated oleandomycin dissociates by the loss of
the hexapyranose moiety in both the IRMPD and CAD
spectra (formation of m/z 544), loss of both sugars
(formation of m/z 387), and by formation of the des-
osamine ion (m/z 158) (IRMPD only). The absence of
dehydration, a loss that was significant for both proton-
ated erythromycin A and B, is accounted for by the lack
of a hydroxyl group at C-6 [5]. Apparently the C-11
hydroxyl group is not a viable route for dehydration in
these macrolides.
Protonated SP1 (with a C-9 hydroxyl instead of a
carbonyl) and SP4 (in which the C-9 oxygen is involved
in binding to the trimethylbenzyl protecting group)
exhibit virtually no water loss in either the CAD or
IRMPD spectra, corroborating the C-6/C-9 oxonium
formation mechanism proposed by Gates et al. [4], in
which the carbonyl oxygen at C-9 was involved in
dehydration. The dissociation spectrum of protonated
SP3 displays a small signal corresponding to water loss;
the presence of a new hydroxyl group at C-3 likely
accounts for this fragmentation pathway. Protonated
Figure 4. (a) CAD and (b) IRMPD of protonated erythromycin
B.
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SP2 undergoes extensive dehydration, thus confirming
that the presence of the C-3 hydroxyl group promotes
dehydration even in the absence of the C-9 carbonyl.
Loss of desosamine as a neutral is a significant pathway
only for protonated SP3, the only compound lacking the
less basic cladinose moiety and in which the C-9 and
C-11 oxygens bridge a trimethylbenzyl substituent, thus
suppressing the typical dehydration pathway.
SP3 and SP4 are interesting cases because both lack
the cladinose sugar, and the active C-9 oxygen (which is
key for the dominant dehydration step in the other
macrolides) is bound to a trimethylbenzyl substituent.
In addition, SP4 lacks the desosamine moiety, and the
C-5 and C-3 oxygens are bound to a p-methoxybenzyl
substituent. For protonated SP3, the loss of the trimeth-
ylbenzyl substituent is a dominant pathway, despite the
fact that this substituent is connected to the macrolide
ring by two carbon™oxygen bonds. One route that
accounts for this loss is shown in Scheme 2a, but the site
of the ionizing proton has not been confirmed. For
protonated SP4, the elimination of the trimethylbenzyl
substituent is not observed; instead, the loss of the other
substituent is dominant (Scheme 2b).
Other than the notable absence of the lower mass
fragment ions in the CAD spectra that are prominent in
the IRMPD spectra, the CAD and IRMPD spectra are
qualitatively similar. In both the IRMPD and CAD
spectra, cleavages of the macrolide ring are absent or
insignificant. Moreover, neither IRMPD nor CAD pro-
vide sufficient diagnostic fragment ions to confirm the
protecting groups at each position of SP4. These latter
two shortcomings prompted our interest in lithium
cationization as an alternative to protonation to pro-
duce precursor ions that potentially would give com-
plementary structural information upon activation.
Lithium Cationized Macrolides
Production of lithium-cationized complexes only re-
quired the addition of a lithium salt to the solutions
containing the macrolides, so it is an easy way to create
ions that may give complementary or more diagnostic
Scheme 2
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structural information compared to that obtained for
protonated molecules. While overall signal intensities
were of the same order of magnitude for either ioniza-
tion technique, the alkali metal complexes tended to
produce more fragments than the protonated counter-
parts upon CAD or IRMPD. Examples of the fragmen-
tation patterns obtained for the lithium-cationized spe-
cies are shown for erythromycin B (Figure 5) and SP4
(Figure 6), and all of the IRMPD and CAD data is
summarized in Table 2.
There are three notable changes in the dissociation
pattern of lithium-cationized erythromycin A compared
to that of protonated erythromycin A. First, dehydra-
tion is generally limited to a single water loss instead of
the two or three seen for protonated erythromycin A. In
addition, two new diagnostic fragment ions are ob-
served for lithium-cationized erythromycin A, one at
m/z 626 and one at m/z 608. A pathway rationalizing the
loss of 114 u is shown in Scheme 3, and clearly cleav-
ages of the macrolide ring are required for this frag-
mentation pathway, a type of process notably absent for
the protonated species. Presumably this type of process
also accounts for the loss of 132 u, which requires the
loss of one water molecule in conjunction with the loss
of 114 u. Cleavages of the macrolide ring were not
observed for the protonated species, suggesting that the
lithium cationization process substantially changes the
activation/dissociation processes of the macrolides. The
macrolide cleavage pathways are somewhat more sig-
nificant for lithium-cationized erythromycin B and ole-
andomycin in which the losses of 98 u or 116 u for
erythromycin B and loss of 84 u for oleandomycin are
analogous to those observed for erythromycin A. The
mass shifts in these neutral losses compared to those
observed for lithium-cationized erythromycin A are
accounted for by the absence of the C-12 hydroxyl
group in erythromycin B (difference of 16 u) and the
lack of the C-12 hydroxy group and C-13 methylene
group in oleandomycin (difference of 30 u). The loss of
84 u does not occur in conjunction with dehydration for
lithium-cationized oleandomycin presumably because
of the absence of the C-6 hydroxyl group, as noted
earlier for the dissociation of protonated oleandomycin.
For lithium-cationized erythromycin A and B, addi-
tional new fragment ions at m/z 450 and 468 indicate
that the macrolide ring cleavage illustrated in Scheme 3
may also occur in conjunction with the standard loss of
the cladinose ring. In fact, for both lithium-cationized
erythromycin A and B, a new fragment ion at m/z 293
appears, attributed to loss of desosamine (157 u) in
combination with the loss of the cladinose moiety and
the diagnostic macrolide ring cleavage. (This fragment
ion is only significant in the IRMPD spectra.) This
combination of neutral losses is supported by multi-
stage IRMPD (MSn) experiments. For lithium-cationized
oleandomycin, the loss of 84 u may occur in conjunction
with the loss of the hexapyranose moiety. A new
fragmentation pathway that emerges for lithium-cation-
ized oleandomycin is the loss of formaldehyde, a pro-
cess that apparently involves the epoxide moiety at the
C-8 position. This simple loss, not observed for proton-
ated oleandomycin, provides a key way to confirm the
epoxide substituent.
Both protonated and lithium-cationized SP1 give one
major fragment, loss of cladinose. Of all the macrolides
analyzed, SP1 shows the fewest differences in the
fragmentation patterns of the protonated and lithium-
cationized species. Two new fragment ions that emerge
for the lithium-cationized species are the loss of cladi-
Figure 5. (a) CAD and (b) IRMPD of lithium-cationized eryth-
romycin B.
Figure 6. CAD of (a) protonated and (b) lithium-cationized
SP4.
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Table 2. CAD and IRMPD data for lithium-cationized macrolides
Compound Parent (m/z) Fragment (m/z) Neutral loss
CAD Results
Percent
IRMPD Results
Percent
Erythromycin A 740 722 18 37% 7%
626 114 2% —
608 132 2% —
582 158 44% 16%
564 176 13% 37%
546 194 1% 5%
468 272 1% —
450 290 1% 13%
293 447 1% 12%
158 582 — 10%
Erythromycin B 724 706 18 23% 3%
706 18 23% 3%
626 98 8% —
608 116 7% 2%
566 158 44% 12%
548 176 8% 10%
468 256 6% 4%
450 274 4% 27%
293 431 1% 17%
275 449 1% 3%
158 566 — 19%
116 610 — 3%
Oleandomycin 694 664 30 13% 1%
610 84 7% 1%
550 144 69% 27
537 157 2% 3%
532 162 3% 1%
466 228 4% 5%
393 301 1% 1%
375 319 1% 1%
309 385 — 1%
158 536 — 55%
116 578 — 4%
SP1 726 568 158 96% 58%
506 220 2% 3%
440 286 1% 2%
411 315 2% 4%
176 550 — 1%
158 568 — 26%
116 612 — 6%
SP2 568 550 18 5% No Data
523 45 3
506 62 33%
498 70 3
494 74 4%
453 115 3%
440 128 8%
411 157 31%
393 175 8%
377 193 2%
SP3 698 680 18 22% No Data
636 62 12%
624 74 4%
582 116 3%
550 148 27%
541 157 6%
530 168 7%
(continued)
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nose in conjunction with either the loss of 62 u, giving
a product at m/z 506, or the loss of 128 u, giving a
fragment ion at m/z 440. These eliminations of 62 or
128 u are highly diagnostic losses discussed later for
lithium-cationized SP2 and SP3, thus representing very
characteristic fragmentation pathways for these three
macrolides.
The fragmentation pattern of lithium-cationized SP2
is much richer than that of the protonated species,
which predominantly lost water and/or desosamine.
Three new fragmentation pathways are the losses of
62 u, 70 u, or 128 u, which may occur consecutively
based on MSn experiments and involve cleavages of the
macrolide ring. Proposed fragments to account for these
losses are illustrated in Scheme 4. The specific site of
dehydration is not known. In addition to the same
fragmentation processes seen for protonated SP3 (i.e.,
dehydration, loss of desosamine, loss of the trimethyl
benzyl group), lithium cationized SP3 also dissociates
by loss of the characteristic 62 u species.
The effect of lithium cationization on the dissociation
of SP4 is especially striking, as illustrated by the CAD
spectra shown in Figure 6. In addition to the dominant
loss of 136 u (the trimethyl benzyl substituent, forma-
tion of m/z 523) that was observed upon dissociation of
protonated SP4, the loss of the other substituent, the
p-methoxybenzyl group (loss of 148 u, formation of m/z
511), is also evident. These losses are depicted in
Scheme 5. In the lithium-containing products shown in
Scheme 5, further hydrogen migrations may occur to
allow favorable delocalization of the charge and multi-
site coordination of lithium. The ability to lose either
substituent likely relates to the greater delocalization of
the lithium ion compared to that of an ionizing proton
in the macrolide.
As noted above in the comparison of the IRMPD and
Table 2. Continued
Compound Parent (m/z) Fragment (m/z) Neutral loss
CAD Results
Percent
IRMPD Results
Percent
523 175 14%
450 248 2%
393 305 3%
SP4 659 641 18 1% 1%
523 136 45% 16%
511 148 44% 22%
479 180 4% 2%
375 284 5% 11%
293 366 1% 8%
277 382 1% 10%
118 541 — 23%
106 553 — 7%
Scheme 3
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CAD spectra for the protonated macrolides, the IRMPD
spectra for the lithium-cationized compounds also
show more intense mid- and lower mass fragment ions,
presumably due to the ability to effectively trap these
ions because the lower mass storage range is not cut off
as in the CAD experiments. Interestingly, the formation
of the desosamine ion at m/z 158 (refer to Scheme 1 for
the proposed structure of this ion) is still observed in
the IRMPD spectra for the lithium-cationized com-
pounds. IRMPD of lithium-cationized SP2 and SP3 was
unsuccessful because of the inadequate ion isolation
capability of the in-house IRMPD/ion trap system, a
problem that potentially will be corrected by the use of
a more advanced arbitrary waveform generator. The
poor isolation is not attributed to the IRMPD experi-
ment itself because isolation was similarly poor when
attempting CAD experiments for SP2 and SP3.
Time-Variable IRMPD and Multi-Stage IRMPD
(MSn)
One way to extend the diagnostic utility of the IRMPD
method is to monitor the IRMPD spectra as a function
of the irradiation time. The resulting time-resolved data
allow selection of the IRMPD conditions for optimiza-
tion of the fragmentation patterns and give an initial
assessment of potential genealogical relationships of the
fragment ions. An example of the time-resolved data
obtained for one of the protonated macrolides, SP1, is
shown in Figure 7. The dominant fragment ion at low
activation times is m/z 562, resulting from the loss of the
cladinose substituent. As the irradiation time increases,
these primary fragment ions absorb sufficient photons
to dissociate, thus causing a reduction in the intensity of
the m/z 562 ion and production of m/z 158, the des-
Scheme 4
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osamine ion. This behavior implies both a genealogical
relationship and allows an effective way to tune the
IRMPD conditions to optimize the formation of specific
fragments for further interrogation.
Discrete stages of isolation and activation give more
specific genealogical information than that obtained by
time-variable IRMPD or energy-variable CAD. Multi-
stage IRMPD (MSn) is particularly efficient because the
losses due to ion scattering that may occur with multi-
ple stages of CAD are virtually eliminated. An example
of the utility of multi-stage IRMPD is shown in Figure 8
for protonated erythromycin B. The IRMPD spectrum is
shown in Figure 8a, and the major fragments are due to
dehydration (m/z 700) or loss of cladinose (m/z 560), or
loss of cladinose and one or two units of water (m/z 542
and 524). In formulating mechanisms to account for
these pathways and to develop predictions for related
analogs, it would be useful to know whether the
macrolide dehydrates prior to or after the loss of
cladinose and whether all of the primary fragments
dissociate further to produce the desosamine ion at m/z
158. In Figure 8b, the IRMPD spectrum obtained for the
dehydrated macrolide is shown. It dissociates by loss of
the cladinose ring, a second water loss, and formation of
the desosamine ion at m/z 158. Figure 8c shows that
isolation and activation of m/z 560, the primary frag-
ment resulting from loss of cladinose from the proton-
ated macrolide, results in dehydration or formation of
m/z 158. Isolation of the secondary fragment ion, m/z
542, indicates that this ion does not dehydrate but
instead dissociates to form the desosamine ion. This
sequence of IRMPD experiments indicates that all of the
primary fragments ultimately may result in the des-
Scheme 5
Figure 7. Time-variable IRMPD of protonated SP1.
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osamine ion, that dehydration and loss of cladinose
may occur in either order, but that if the protonated
macrolide loses the cladinose moiety, it may not un-
dergo two stages of dehydration. The multi-stage
IRMPD spectral results are summarized in Table 3.
For protonated erythromycin A, a second stage of
IRMPD on the fragment ion at m/z 576 (due to loss of
cladinose) formed upon IRMPD of the protonated mac-
rolide indicates that this fragment ion may undergo up
to three steps of dehydration, whereas protonated
erythromycin A undergoes only two steps of dehydra-
tion. This additional step of dehydration for the m/z 576
fragment suggests that the hydroxyl group at the C-3
position (see Scheme 1), involved in a glycosidic bond
for protonated erythromycin A, may be key for this
process. The multi-stage IRMPD spectra for the frag-
ment ion at m/z 158 is identical for both protonated
erythromycin A and B.
The IRMPD spectrum of the m/z 562 fragment from
protonated SP1 gives the same dominant fragment ions
that are observed for protonated SP1. This suggests that
many of the lower mass fragment ions may occur
through consecutive dissociation steps after loss of the
cladinose sugar. For protonated SP2, a similar behavior
is observed, in which IRMPD of m/z 544, formed upon
dehydration of protonated SP2, gives the same four
most dominant fragment ions as observed for IRMPD of
protonated SP2. These four ions, m/z 176, 158, 138, and
116, are all characteristic of the desosamine moiety.
Protonated SP3 produced m/z 544 (loss of the trimethyl
benzyl substituent) as the second most dominant frag-
ment ion upon IRMPD. IRMPD of this primary frag-
ment ion again resulted in the ions diagnostic for the
desosamine moiety. Upon activation protonated SP4
dissociated by loss of the methoxybenzyl substituent
(136 u) as one of the major characteristic pathways.
Isolation and IRMPD of this fragment ion (m/z 517)
predominantly results in the loss of the other substitu-
ent, the trimethyl benzyl moiety (148 u), which may
occur in conjunction with dehydration.
Multi-stage IRMPD experiments are particularly use-
ful for probing the fragmentation pathways of the
lithium-cationized compounds in greater detail because
more extensive cleavages of the macrolide ring are
involved rather than just simple losses of the substitu-
ents or sugars. For example, two of the macrolide ring
cleavages that were observed upon IRMPD of lithium-
cationized erythromycin A were loss of 114 u (proposed
in Scheme 3) or loss of 132 u (presumably loss of 114 u
in conjunction with dehydration). IRMPD allows fur-
ther confirmation of these pathways, as summarized in
Table 3. A second stage of IRMPD on m/z 582 (loss of
cladinose) results in the loss of 132 u (formation of m/z
450) or loss of water (formation of m/z 564). IRMPD of
m/z 450 results in the loss of the desosamine moiety as
the dominant fragment ion (formation of m/z 293). A
third stage of IRMPD on m/z 293 yields the diagnostic
loss of 62 u seen for many of the other lithium-
cationized compounds (i.e., Scheme 4). This series of
IRMPD experiments indicates that the loss of water that
occurs in conjunction with the diagnostic macrolide
cleavage (loss of 114 u) may occur either before or after
the loss of 114 u, and likewise the loss of 114 u may
occur before or after the loss of the cladinose moiety.
For lithium-cationized erythromycin B, a similar gene-
alogical pattern is observed, with the diagnostic macro-
lide ring cleavage (loss of 98 u) occurring before or after
dehydration and before or after the loss of cladinose.
Multi-stage IRMPD confirms the genealogical relation-
ships illustrated in Scheme 4 for lithium-cationized SP1
and SP2, in which activation of m/z 506 produces
fragment ions at both m/z 436 and 378. Loss of the
desosamine moiety (157 u) is also possible from m/z 506.
Multi-stage IRMPD of lithium-cationized SP4 confirms
that loss of either the trimethyl benzene or methoxy-
benzene substituent may occur first. In general, the
multi-stage IRMPD spectra provide more specific frag-
mentation information than just a single stage of
IRMPD, giving greater diagnostic identification of the
macrolides when present in mixtures and allowing
construction of self-consistent fragmentation pathways.
Figure 8. IRMPD mass spectra of protonated erythromycin B. (a)
IRMPD of protonated erythromycin B. (b) IRMPD/IRMPD of the
fragment ion at m/z 700 from protonated erythromycin B. (c)
IRMPD/IRMPD of the fragment ion at m/z 560 from protonated
erythromycin B. (d) IRMPD/IRMPD/IRMPD of the fragment ion
at m/z 542 from m/z 560 from protonated erythromycin B.
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Table 3. Multi-step IRMPD results
Protonated
compounds
Compound
IRMPD
step
Parent (m/z)
or sequence
Fragment
(m/z) Neutral loss Percent
Erythromycin A 1a 734 716 18 6%
698 36 6%
576 158 21%
558 176 6%
540 194 6%
522 212 10%
316 418 2%
158 576 40%
116 618 3%
2 7343 5763 558 18 6%
540 36 7%
522 54 7%
158 418 72%
116 460 8%
3 7343 5763 158 116 42 25%
114 44 24%
98 60 12%
83 75 39%
Erythromycin B 1 718 700 18 12%
560 158 11%
542 176 8%
524 194 57%
316 402 1%
158 560 10%
116 602 1%
2 7183 7003 542 158 13%
524 176 40%
158 542 43%
116 584 4%
2 7183 5603 542 18 26%
158 402 65%
116 444 9%
3 7183 7183 5243 302 222 9%
148 366 84%
116 408 7%
3 7183 5603 542 158 384 90%
116 426 10%
3 7183 5603 158 116 42 22%
98 60 20%
83 75 19%
Oleandomycin 1 688 544 144 42%
302 386 1%
158 530 54%
116 572 3%
2 6883 544 158 386 96%
116 428 4%
SP1 1 720 562 158 42%
544 176 2%
316 404 1%
176 544 2%
158 562 49%
116 604 4%
(continued)
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Table 3. Continued
Protonated
compounds
Compound
IRMPD
step
Parent (m/z)
or sequence
Fragment
(m/z) Neutral loss Percent
2 7203 5623 544 18 3%
405 157 1%
387 175 1%
369 193 1%
351 211 1%
267 295 2%
176 386 3%
158 404 78%
138 424 2%
116 446 10%
SP2 1 562 544 18 3%
387 175 1%
351 211 2%
267 295 2%
176 386 3%
158 404 75%
138 424 2%
2 5623 5443 176 368 10%
158 386 58%
138 406 11%
116 428 21%
3 5623 5443 1763 158 18 89%
116 60 11%
SP3 1 692 674 18 1%
544 148 24%
535 157 1%
526 166 2%
517 175 1%
387 305 2%
369 323 1%
351 341 2%
267 425 2%
176 516 6%
158 534 53%
138 554 3%
116 576 4%
2 6923 5443 176 368 30%
158 386 49%
138 406 14%
116 428 7%
SP4 1 653 635 18 1%
517 136 13%
505 148 1%
487 166 4%
369 284 13%
351 302 29%
333 320 9%
266 387 5%
241 412 7%
227 426 9%
120 533 9%
2 6533 5173 369 148 34%
351 166 32%
(continued)
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Table 3. Continued
Protonated
compounds
Compound
IRMPD
step
Parent (m/z)
or sequence
Fragment
(m/z) Neutral loss Percent
241 276 15%
227 290 19%
Lithiated compounds
Compound IRMPD
step
Parent (m/z)
or sequence
Fragment
(m/z)
Neutral loss Percent
Erythromycin A 1 740 722 18 7%
582 158 16%
564 176 37%
546 194 5%
450 290 13%
293 447 12%
158 582 10%
2 7403 5823 564 18 55%
450 132 25%
407 175 12%
394 188 8%
2 7403 5643 546 18 3%
450 114 12%
407 157 4%
389 175 4%
293 271 14%
275 289 7%
231 333 12%
223 341 23%
191 373 14%
158 406 7%
2 7403 4503 407 43 22%
293 157 78%
3 7403 5643 2933 275 18 12%
231 62 15%
191 102 38%
179 114 10%
173 120 12%
161 132 13%
Erythromycin B 1 724 706 18 3%
608 116 2%
566 158 12%
548 176 10%
468 256 4%
450 274 27%
293 431 17%
275 449 3%
158 566 19%
116 610 3%
2 7243 5663 548 18 14%
468 98 5%
450 116 39%
409 157 2%
391 175 4%
293 273 24%
275 291 6%
231 335 6%
2 7243 5483 468 80 2%
450 98 31%
(continued)
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Table 3. Continued
Protonated
compounds
Compound
IRMPD
step
Parent (m/z)
or sequence
Fragment
(m/z) Neutral loss Percent
432 116 3%
409 139 2%
391 157 4%
293 255 26%
275 273 7%
231 317 8%
188 360 13%
158 408 6%
2 7243 4503 409 41 2%
391 59 2%
321 129 4%
293 157 36%
275 175 9%
231 219 15%
191 259 19%
158 292 13%
3 7243 5483 2933 275 18 8%
249 44 5%
231 62 29%
219 74 6%
191 102 52%
Oleandomycin 1 694 664 30 1%
610 84 1%
550 144 27%
537 157 3%
532 162 1%
466 228 5%
393 301 1%
375 319 1%
309 385 1%
158 536 55%
116 578 4%
2 6943 5503 520 30 2%
466 84 17%
393 157 4%
375 175 3%
309 241 14%
291 259 5%
217 333 6%
158 392 37%
138 412 4%
116 434 8%
2 6943 4663 404 62 4%
392 74 3%
351 115 3%
309 157 31%
291 175 13%
263 203 10%
235 231 10%
229 237 8%
217 249 12%
158 308 6%
3 6943 4663 3093 291 18 13%
263 46 19%
247 62 10%
(continued)
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Table 3. Continued
Protonated
compounds
Compound
IRMPD
step
Parent (m/z)
or sequence
Fragment
(m/z) Neutral loss Percent
235 74 10%
201 108 30%
173 136 18%
SP1 1 726 568 158 58%
506 220 3%
440 286 2%
411 315 4%
176 550 1%
158 568 26%
116 612 6%
2 7263 5683 550 18 2%
506 62 13%
440 128 7%
422 146 5%
411 157 21%
393 175 10%
375 193 18%
349 219 6%
283 285 7%
265 303 11%
3 7263 5683 5063 436 70 7%
378 128 68%
349 157 8%
203 303 17%
3 7263 5683 4403 422 18 15%
378 62 26%
265 175 14%
221 219 10%
203 237 21%
163 277 14%
3 7263 5683 4113 393 18 10%
349 62 9%
283 128 17%
265 146 21%
221 190 19%
203 208 12%
163 248 12%
3 7263 5683 3933 375 18 12%
295 98 8%
265 128 17%
221 172 8%
203 190 18%
193 200 16%
179 214 13%
163 230 8%
3 7263 5683 3753 357 18 3%
305 70 5%
221 154 10%
203 172 36%
179 196 21%
163 212 25%
SP4 1 659 641 18 1%
523 136 16%
(continued)
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Conclusions
Three main conclusions are derived from the present
comparison of IRMPD and CAD for structural charac-
terization of protonated and lithium-cationized macro-
lides. First, the IRMPD spectra contain key diagnostic
fragment ions, especially the desosamine ion, not ob-
served in the CAD spectra because of the trapping
limitations that occur when higher mass ions are reso-
nantly activated in the ion trap and/or lack of forma-
tion of these ions under CAD conditions. Second, multi-
stage IRMPD proves particularly useful for confirming
the genealogical relationships of dissociation, especially
when low mass fragment ions that are not effectively
stored under CAD conditions are formed, which ulti-
mately gives support to the proposed fragmentation path-
ways and fragment ion structures. Third, the lithium-
cationization process results in more extensive and more
diagnostic fragmentation than that observed for the pro-
tonated macrolides. In particular, mapping of the substitu-
ents for the synthetic precursors is possible for the lithium-
cationized complexes because the losses of the
substituents are observed directly upon IRMPD or CAD.
Moreover, characteristic cleavages of the macrolide rings
are evident for the lithium-cationized complexes.
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